Rob Rodrigues surveys Brazil’s patent enforcement landscape, highlighting rapid preliminary injunctions and their impact on multinational patent strategy.
On-demand Global IP Spotlight briefing on Latin America covering AI, SEPs, pharmaceuticals, patent prosecution and oppositions, with takeaways for U.S. stakeholders.
Brazil's 2025 SEP litigation experienced significant growth, with Rio courts becoming a key forum, marked by procedural innovations, FRAND emphasis, and emerging connected-car disputes.
Fulbright Medical’s Shanghai Stock Exchange IPO was terminated after extensive Johnson & Johnson patent litigation, including multiple infringement suits and rising damages claims.
Evidence-based analysis shows biopharmaceutical patents are not excessive, do not create thickets, and can support timely generic competition and real innovation.
Anvisa’s new note supports biosimilar interchangeability in Brazil, aligning with global practice and reinforcing safeguards for switching and traceability.
Anvisa’s new technical note recognizes biosimilar interchangeability in Brazil, reinforcing comparability, traceability and pharmacovigilance safeguards.
Brazil's Ministry of Health issued a new methodology for valuing technology transfer in PDPs, establishing pricing benchmarks and reimbursement rules for IP.
Silimed secured a Munich PI against Polytech over EP2581193, halting polyurethane-coated implant manufacture and sales in Germany amid parallel UPC action.
.webp){kind=avatar}
.png){kind=avatar}
